科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

国庆日翌日休市 09-29 16:08:22

8.340

-0.410

-4.69%

最高8.610	最低8.120	成交量32.30万
今开8.130	昨收8.750	日振幅5.60%
总市值47.99亿	流通市值47.99亿	总股本5.75亿
成交额267.46万	换手率0.06%	流通股本5.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":8.34,"timestamp":1695974902031,"preClose":8.75,"halted":0,"volume":323000,"delay":0,"floatShares":575371079,"shares":575371079,"eps":-1.7352068,"marketStatus":"国庆日翌日休市","marketStatusCode":7,"change":-0.41,"latestTime":"09-29 16:08:22","open":8.13,"high":8.61,"low":8.12,"amount":2674585,"amplitude":0.056,"askPrice":8.46,"askSize":500,"bidPrice":8.34,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.7800480492202615,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1696296600000},"adr":0,"listingDate":1623945600000,"adjPreClose":8.75,"volumeRatio":0.6551724137665245,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2371381450","title":"科济药业-B盘中异动 大幅跳水7.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2371381450","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2371381450?lang=zh_cn&edition=full","pubTime":"2023-09-29 10:00","pubTimestamp":1695952827,"startTime":"0","endTime":"0","summary":"2023年09月29日早盘10时00分，科济药业-B股票出现波动，股价急速下挫7.08%。科济药业-B股票所在的生物技术行业中，整体跌幅为0.55%。消息层面，截至10时00分，科济药业-B股票正面舆情新闻比例7.69%。《科济药业-B：CLAUDIN18.2CAR-T治疗胰腺癌病例报告发表于国际学术期刊》资讯为影响科济药业-B的重要信息。该信息摘要如下：事件：科济药业宣布自研靶向Claudin18.2 的CAR-T 细胞CT041 治疗转移性胰腺癌的两个病例报告在《Journal of Hematology & Oncology》发表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230929100027838fc055&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230929100027838fc055&s=b","is_publish_highlight":false},{"id":"2371376089","title":"科济药业-B（02171.HK）：9月28日南向资金增持4.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2371376089","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2371376089?lang=zh_cn&edition=full","pubTime":"2023-09-29 06:01","pubTimestamp":1695938496,"startTime":"0","endTime":"0","summary":"9月28日北向资金增持4.4万股科济药业-B。近5个交易日中，获南向资金增持的有4天，累计净增持31.8万股。截至目前，南向资金持有科济药业-B9935.2万股，占公司已发行普通股的17.26%。科济药业控股有限公司是一家主要从事创新嵌合抗原受体T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230929060142840d57c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230929060142840d57c2&s=b","is_publish_highlight":false},{"id":"2370225728","title":"国盛证券：维持科济药业-B(02171)“买入”评级 长期看好公司发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2370225728","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370225728?lang=zh_cn&edition=full","pubTime":"2023-09-28 14:46","pubTimestamp":1695883613,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。潜在首款实体瘤CAR-T疗法CT041已进入确证性临床，合作Moderna拓宽应用边界。本次与Moderna达成合作，CT041联用CLDN18.2mRNA癌症疫苗开展临床前研究和I期临床，公司研发能力获得海外药企认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1001094.html","is_publish_highlight":false},{"id":"2370749941","title":"【券商聚焦】国盛证券维持科济药业(02171)“买入”评级 长期看好公司发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2370749941","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2370749941?lang=zh_cn&edition=full","pubTime":"2023-09-28 11:29","pubTimestamp":1695871795,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国盛证券发研报指，科济药业-B 宣布自研靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告在《Journal of Hematology & Oncology》发表。科济药业宣布与美德纳公司已启动一项合作协议，以研究科济药业的Claudin18.2 CAR-T候选产品与美德纳的试验性Claudin18.2 mRNA癌症疫苗的组合效果。针对CLDN18.2阳性消化道肿瘤的CT041和针对肝癌的CT011研发全球领先，产品设计差异化、布局全球化。该行长期看好公司发展，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=d7d9d2b698b530007ef0b8361f686735","is_publish_highlight":false},{"id":"2370611227","title":"科济药业-B(02171.HK)：CLAUDIN18.2CAR-T治疗胰腺癌病例报告发表于国际学术期刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2370611227","media":"国盛证券","top":-1,"share":"https://www.laohu8.com/m/news/2370611227?lang=zh_cn&edition=full","pubTime":"2023-09-27 20:41","pubTimestamp":1695818498,"startTime":"0","endTime":"0","summary":"事件：科济药业宣布自研靶向Claudin18.2 的CAR-T 细胞CT041 治疗转移性胰腺癌的两个病例报告在《Journal of Hematology & Oncology》发表。输注后患者出现2 级CRS，经托珠单抗治疗后恢复。截至2023 年7 月末次随访时患者仍处于持续缓解状态。本次与Moderna 达成合作，CT041 联用CLDN18.2 mRNA 癌症疫苗开展临床前研究和I 期临床，公司研发能力获得海外药企认可。针对CLDN18.2阳性消化道肿瘤的CT041 和针对肝癌的CT011 研发全球领先，产品设计差异化、布局全球化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927204141826eef6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927204141826eef6d&s=b","is_publish_highlight":false},{"id":"2369380175","title":"科济药业CT041治疗胰腺癌案例发表于《Journal of Hematology & Oncology》","url":"https://stock-news.laohu8.com/highlight/detail?id=2369380175","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2369380175?lang=zh_cn&edition=full","pubTime":"2023-09-21 15:14","pubTimestamp":1695280440,"startTime":"0","endTime":"0","summary":"上海2023年9月21日 /美通社/ --科济药业，一家主要专注于治疗血液恶性肿瘤和实体瘤的创新CAR-T细胞疗法公司，宣布公司自主研发的靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告已在《Journal of Hematology & Oncology》杂志发表，题为\"CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer\"。病例1为一名58岁的女性胰腺癌患者，伴有肺及淋巴结转移。科济药业首席医学官Raffaele Baffa博士表示：\"非常高兴看到我们的CT041在治疗转移性胰腺癌的两个案例在《Journal of Hematology & Oncology》上发表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4216486_ZH16486_1","is_publish_highlight":false},{"id":"2368169578","title":"科济药业-B09月20日主力资金流出59万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2368169578","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2368169578?lang=zh_cn&edition=full","pubTime":"2023-09-20 16:16","pubTimestamp":1695197807,"startTime":"0","endTime":"0","summary":"09月20日, 科济药业-B股价跌0.65%，报收9.12元，成交金额298万元，换手率0.06%，振幅2.51%，量比0.70。科济药业-B今日主力资金净流出59万元，连续3日净流出，上一交易日主力净流出0万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为45.45%，平均跌幅为3.28%。该股近5个交易日下跌0.76%，主力资金累计净流入84万元；近20日主力资金累计净流出101万元，其中净流出天数为7日。该股主力净额占比0.01%，港股市场排名2453/2615。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230920161718825a89a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230920161718825a89a9&s=b","is_publish_highlight":false},{"id":"2367636826","title":"科济药业-B盘中异动 早盘股价大跌5.17%报8.441港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2367636826","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2367636826?lang=zh_cn&edition=full","pubTime":"2023-09-15 09:52","pubTimestamp":1694742726,"startTime":"0","endTime":"0","summary":"2023年09月15日早盘09时52分，科济药业-B股票出现波动，股价大幅跳水5.17%。截至发稿，该股报8.441港元/股，成交量20.45万股，换手率0.04%，振幅6.97%。科济药业-B股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，中国抗体-B、圣诺医药-B、荣昌生物涨幅较大，振幅较大的相关个股有来凯医药-B、科济药业-B、复宏汉霖，振幅分别为7.56%、6.52%、5.55%。消息层面，截至09时52分，科济药业-B股票正面舆情新闻比例33.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915095206838bf249&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915095206838bf249&s=b","is_publish_highlight":false},{"id":"2365293062","title":"科济药业-B（02171.HK）：9月5日南向资金增持18.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2365293062","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2365293062?lang=zh_cn&edition=full","pubTime":"2023-09-06 03:41","pubTimestamp":1693942899,"startTime":"0","endTime":"0","summary":"9月5日北向资金增持18.15万股科济药业-B。近20个交易日中，获南向资金增持的有11天，累计净增持65.8万股。截至目前，南向资金持有科济药业-B9904.7万股，占公司已发行普通股的17.21%。科济药业控股有限公司是一家主要从事创新嵌合抗原受体T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230906034214822e4a23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230906034214822e4a23&s=b","is_publish_highlight":false},{"id":"2362182543","title":"天士力(600535.SH)：拟清仓减持所持科济药业股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2362182543","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2362182543?lang=zh_cn&edition=full","pubTime":"2023-08-26 15:20","pubTimestamp":1693034429,"startTime":"0","endTime":"0","summary":"科济药业是一家在中国及美国开展业务的生物制药公司，主要专注于治疗血液瘤和实体瘤的创新CAR-T细胞疗法。科济药业于2021年6月在港交所上市，公司持有科济药业11,111,112.00股份，占其当时发行股份的1.96%。截至2022年底，公司已通过香港证券交易所处置持有股票的34.20%，成交金额5,070.70万元人民币。目前公司尚持有科济药业7,311,112股，截至2023年6月30日，该部分股份的账面价值为6,531.74万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230826152033820a3b10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230826152033820a3b10&s=b","is_publish_highlight":false},{"id":"2362239099","title":"科济药业-B(02171)CAR-T美国产能就绪，实体瘤值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2362239099","media":"国金证券","top":-1,"share":"https://www.laohu8.com/m/news/2362239099?lang=zh_cn&edition=full","pubTime":"2023-08-25 17:17","pubTimestamp":1692955024,"startTime":"0","endTime":"0","summary":"点评CAR-T疗法管线布局全面，实体瘤突破值得期待。此外，GPC3CAR-T处于I期临床试验及CLDN18.2单抗处于Ib期临床试验阶段。公司具备质粒、慢病毒载体和CAR-T细胞产品的一体化生产能力。BD持续推进，BCMACAR-T推广提速。2023年1月，公司与 华东医药 签署在中国大陆地区商业化BCMACAR-T签订合作协议。NCorporation订立许可协议，在韩国开发及商业化CT032和BCMACAR-T，用于多种癌症的潜在治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308251730548207edc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308251730548207edc7&s=b","is_publish_highlight":false},{"id":"2362198639","title":"科济药业-B现涨超4% 西南证券指CT041研发进展提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2362198639","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2362198639?lang=zh_cn&edition=full","pubTime":"2023-08-25 10:49","pubTimestamp":1692931783,"startTime":"0","endTime":"0","summary":"科济药业-B（02171）早盘上涨4.41%，现报9.70港元，成交额526.20万港元。\n　　西南证券表示，公司核心品种CT053上市在即，在研品种逐步进入收获期，预计公司2023-2025年收入分别为2.2、1.6和7亿元。该行表示，核心品种CT053（BCMACAR-T）落地在即，美国和加拿大Ⅱ期入组正在进行中；CT041启动美国Ⅱ期，研发进展提速。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imziknye1459132.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-08-25/doc-imziknye1459132.shtml","is_publish_highlight":false},{"id":"2362915231","title":"【港股通】科济药业-B(02171)涨4.74% 机构看好其未来发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2362915231","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2362915231?lang=zh_cn&edition=full","pubTime":"2023-08-25 10:15","pubTimestamp":1692929730,"startTime":"0","endTime":"0","summary":"截至发稿，科济药业-B(02171)涨4.74%，报9.73港元。消息面上，科济药业近日公布6月止六个月中期业绩，亏损由上年同期3.76亿人民币(下同)，扩至4.04亿元，每股亏损73分。不派中期息。国泰君安发研报称公司CT053国内上市在即、华东医药有望助力商业化放量，CT041 研发进展顺利，看好公司未来发展。维持增持评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=96b67073e5dfdcbf2d97316255322094","is_publish_highlight":false},{"id":"2362913010","title":"港股异动 | 科济药业-B(02171)涨近7% 中期亏损同比扩大 核心品种CT053上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2362913010","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2362913010?lang=zh_cn&edition=full","pubTime":"2023-08-25 09:56","pubTimestamp":1692928597,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B(02171)现涨近7%，截至发稿，涨5.6%，报9.81港元，成交额441.56万港元。消息面上，科济药业发布中期业绩，净亏损4.04亿元人民币，同比扩大7.48%；经调整净亏损3.86亿元，同比扩大9.31%。西南证券表示，公司核心品种CT053上市在即，在研品种逐步进入收获期，预计公司2023-2025年收入分别为2.2、1.6和7亿元。该行表示，核心品种CT053(BCMACAR-T)落地在即，美国和加拿大Ⅱ期入组正在进行中；CT041启动美国Ⅱ期，研发进展提速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/982321.html","is_publish_highlight":false},{"id":"2361668699","title":"科济药业2023年中报点评: BCMA CAR-T即将获批，CLDN18.2 CAR-T关键性临床进展顺利【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2361668699","media":"国广有话说","top":-1,"share":"https://www.laohu8.com/m/news/2361668699?lang=zh_cn&edition=full","pubTime":"2023-08-24 22:10","pubTimestamp":1692886240,"startTime":"0","endTime":"0","summary":"2022年10月CDE已受理NDA，并将该申请纳入优先审评，预期CT053将于2023年底或2024年初获批上市。CT053目前在北美正在进行2期临床试验，预计2025H1提交BLA，计划开展早线治疗的临床探索。实体瘤CAR-T数据亮眼，合作推动全球价值提升：CT041是全球首个且唯一进入确证性II期临床的实体瘤CAR-T品种，针对Claudin18.2阳性晚期胃癌适应症。维持“买入”评级。本公司不会因接收人收到本报告而视其为客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082422201982055ec8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082422201982055ec8&s=b","is_publish_highlight":false},{"id":"2361956359","title":"科济药业-B(02171)2023年半年报点评：CT053落地在即，全球产能持续扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2361956359","media":"西南证券","top":-1,"share":"https://www.laohu8.com/m/news/2361956359?lang=zh_cn&edition=full","pubTime":"2023-08-24 18:14","pubTimestamp":1692872047,"startTime":"0","endTime":"0","summary":"事件：公司发布2023年半年度报告，经调整净亏损为3.9亿元，较2022年3.5亿元增加0.3亿元。截至2023年6月30日，现金及现金等价物为21.7亿元。核心品种CT053落地在即，美国和加拿大Ⅱ期入组正在进行中。CT053的NDA申请已于2022年10月18日获国家药监局受理，预计2023年底或2024年初获批上市；在美国及加拿大进行的Ⅱ期临床试验的入组正在进行中，预计2025年初向FDA提交BLA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082418303184326144&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082418303184326144&s=b","is_publish_highlight":false},{"id":"2361934368","title":"科济药业(02171)：国内商业化在即 海外可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2361934368","media":"浙商证券","top":-1,"share":"https://www.laohu8.com/m/news/2361934368?lang=zh_cn&edition=full","pubTime":"2023-08-24 16:11","pubTimestamp":1692864714,"startTime":"0","endTime":"0","summary":"投资要点我们看好公司作为全球实体瘤CAR-T 龙头企业，其CT053、CT041 等管线陆续商业化带来成长性。CT053：国内获批在即，美国望2025H1 提交BLA2022 年10 月，NMPA 已受理zevor-cel 的NDA 申请，并将其纳入优先审评。在美国及加拿大进行的II 期临床试验的入组正在进行中。根据公司中报披露：“公司计划在2023 年底完成海外II 期临床大约100 名患者入组，并计划2025H1向FDA 提交BLA”。公司也批露计划在2024 年向CDE提交治疗晚期胃癌的NDA，2025 年向FDA 提交治疗晚期胃癌的BLA 申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082416115882048aa4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082416115882048aa4&s=b","is_publish_highlight":false},{"id":"2361939068","title":"高盛：维持科济药业(02171)“买入”评级 目标价削41%至17.51港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2361939068","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2361939068?lang=zh_cn&edition=full","pubTime":"2023-08-24 15:54","pubTimestamp":1692863642,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研究报告称，维持科济药业(02171)“买入”评级，相信其现金水平能支撑到2026年，但目标价由29.67港元削41%至17.51港元。报告中称，公司上半年亏损4.04亿元人民币大致符合预期，但在生物技术资金环境紧绌下，视前景不明的欧盟及日本市场为非核心市场，认为将专注于中国及美国市场。该行调整公司2023至24年每股亏损预测，由1.38/1.95元人民币调整至1.61/1.21元人民币，以反映移除欧盟及日本市场的销售、微调销售轨道及经营支出预测、首付款最新的确认时间，以及汇率更新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/981300.html","is_publish_highlight":false},{"id":"2361987169","title":"科济药业-B盘中异动 下午盘股价大涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2361987169","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2361987169?lang=zh_cn&edition=full","pubTime":"2023-08-24 13:10","pubTimestamp":1692853825,"startTime":"0","endTime":"0","summary":"2023年08月24日下午盘13时10分，科济药业-B股票出现波动，股价急速拉升5.38%。科济药业-B股票所在的生物技术行业中，整体涨幅为2.36%。消息层面，截至13时10分，科济药业-B股票正面舆情新闻比例35.71%。该信息摘要如下：科济药业-B发布截至2023年6月30日止六个月中期业绩，净亏损4.04亿元，同比扩大7.48%;经调整净亏损3.86亿元，同比扩大9.31%;每股净亏损0.73元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082413102582ed93ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082413102582ed93ce&s=b","is_publish_highlight":false},{"id":"2361607123","title":"科济药业-B(02171.HK)：继续推进核心产品商业化与技术升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2361607123","media":"国联证券","top":-1,"share":"https://www.laohu8.com/m/news/2361607123?lang=zh_cn&edition=full","pubTime":"2023-08-24 08:21","pubTimestamp":1692836494,"startTime":"0","endTime":"0","summary":"事件：公司发布2023 年中期业绩报告，目前尚无产品获批上市与销售收益。截至2023 年6 月30 日，公司现金储备为21.74 亿元人民币。CLDN18.2 CAR-T CT041在全球率先进入II 期临床，其治疗≧3 线胃癌的临床数据显著优于现有PD-L1 等药物，预计将于2024 年在中国提交NDA，2025 年在美国提交BLA，有望成为全球首个商业化实体瘤CAR-T 产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082408214082035bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082408214082035bd7&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0935},{"period":"1month","weight":-0.1212},{"period":"3month","weight":-0.1393},{"period":"6month","weight":-0.3433},{"period":"1year","weight":-0.2735},{"period":"ytd","weight":-0.4433}],"websiteUrl":"http://www.carsgen.com","compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0364},{"period":"3month","weight":-0.0585},{"period":"6month","weight":-0.127},{"period":"1year","weight":0.0375},{"period":"ytd","weight":-0.0997}],"name":"科济药业-B","description":"科济药业控股有限公司是一家主要从事创新嵌合抗原受体（CAR）T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。该公司已开发升级版靶向B细胞成熟抗原（BCMA）的CAR-T产品CT053。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","exchange":"SEHK","nameEN":"CARSGEN-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.17.2","shortVersion":"4.17.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}